Exagen (NASDAQ:XGN) Stock: Insider Jorey Chernett Sells 58,068 Shares

Posted by Lindsey Winhoffer on Nov 15th, 2026

Exagen Inc. (NASDAQ:XGN – Get Free Report) major shareholder Jorey Chernett sold 58,068 shares of the firm’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $4.08, for a total value of $236,917.44. Following the completion of the transaction, the insider owned 2,529,436 shares in the company, valued at approximately $10,320,098.88. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

On Thursday, November 12th, Jorey Chernett sold 109,436 shares of Exagen stock. The stock was sold at an average price of $4.65, for a total value of $508,877.40.
On Wednesday, November 11th, Jorey Chernett acquired 71,315 shares of Exagen stock. The shares were purchased at an average price of $5.23 per share, with a total value of $372,977.45.
On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The shares were sold at an average price of $6.14, for a total value of $69,167.10.
On Tuesday, November 10th, Jorey Chernett bought 7,085 shares of Exagen stock. The stock was purchased at an average cost of $5.26 per share, for a total transaction of $37,267.10.
On Monday, November 9th, Jorey Chernett bought 8,500 shares of Exagen stock. The stock was purchased at an average cost of $6.35 per share, for a total transaction of $53,975.00.
On Monday, October 19th, Jorey Chernett bought 14,000 shares of Exagen stock. The stock was purchased at an average cost of $7.46 per share, for a total transaction of $104,440.00.

Exagen Stock Performance

Shares of Exagen stock traded down $0.28 during trading hours on Friday, reaching $4.13. 3,356,140 shares of the stock traded hands, compared to its average volume of 581,895. The company has a 50 day moving average price of $7.71 and a 200 day moving average price of $5.13. The firm has a market capitalization of $105.36 million, a price-to-earnings ratio of -5.51 and a beta of 2.25. Exagen Inc. has a one year low of $2.59 and a one year high of $9.28. The company has a quick ratio of 3.18, a current ratio of 3.46 and a debt-to-equity ratio of 1.73.

Exagen (NASDAQ:XGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Exagen had a negative net margin of 25.14% and a negative return on equity of 125.60%. The business had revenue of $18.42 million for the quarter, compared to analysts’ expectations of $18.34 million. On average, equities research analysts expect that Exagen Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LP bought a new position in shares of Exagen during the 2nd quarter valued at approximately $52,000. Penbrook Management LLC purchased a new stake in Exagen in the 3rd quarter worth approximately $92,000. Calamos Advisors LLC bought a new stake in Exagen during the 3rd quarter worth approximately $94,000. Bank of New York Mellon Corp bought a new stake in Exagen during the 2nd quarter worth approximately $97,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Exagen by 137.4% during the first quarter. Dimensional Fund Advisors LP now owns 62,571 shares of the company’s stock valued at $188,000 after purchasing an additional 36,213 shares in the last quarter. Institutional investors own 75.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Exagen from a “hold” rating to a “sell” rating in a research report on Saturday. TD Cowen lifted their price target on shares of Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. B. Riley Financial initiated coverage on shares of Exagen in a research report on Friday, September 11th. They set a “buy” rating and a $12.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Exagen in a research report on Wednesday, November 4th. Finally, Canaccord Genuity Group reduced their price objective on Exagen from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.88.

Get Our Latest Stock Report on XGN

About Exagen

(Get Free Report)

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.